Razoxane

CAS No. 21416-67-1

Razoxane( 4,4'-propylenebis(piperazine-2,6-dione) )

Catalog No. M27828 CAS No. 21416-67-1

Razoxane is used as an antimitotic agent with immunosuppressive properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 93 In Stock
5MG 85 In Stock
10MG 136 In Stock
25MG 255 In Stock
50MG 398 In Stock
100MG 616 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Razoxane
  • Note
    Research use only, not for human use.
  • Brief Description
    Razoxane is used as an antimitotic agent with immunosuppressive properties.
  • Description
    Razoxane is used as an antimitotic agent with immunosuppressive properties.(In Vivo):This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. Early treatment with razoxane (30 mg/kg i.p. from day -2 to +14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59.9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3.4 per cent and 26.1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.
  • In Vitro
    Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
  • In Vivo
    Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Animal Model:Sprague-Dawley ratsDosage:30 mg/kg or 10 mg/kg per day Administration:Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result:Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
  • Synonyms
    4,4'-propylenebis(piperazine-2,6-dione)
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Topoisomerase
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    21416-67-1
  • Formula Weight
    268.273
  • Molecular Formula
    C11H16N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.KunchengQiu, et al. Protective effect of total glycosides from lily on H2O2-induced H9C2 cells mitochondrial damage and characterization of the chemical profiles by UHPLC-LTQ-Orbitrap-MSn. Journal of Functional Foods. Volume 71, August 2020, 104036
molnova catalog
related products
  • Eleutherin

    Eleutherin is a type of naphthoquinone derivative with the protective effect against the injury ofhuman umbilical vein endothelial cells (HUVECs), which can be isolated from the edible bulbs of Eleutherine americana (Hong-Cong).

  • Gimatecan

    Gimatecan (STI481) is a potent topoisomerase I inhibitor. Gimatecan is an orally bioavailable camptothecin analogue with antitumor activity.

  • Lucidin primeverosid...

    Lucidin primeveroside is a natural product isolated from the root powder of akane (Rubia akane) and can be used as a coloring agent and a food pigment. Lucidin primeveroside can be metabolically converted to genotoxic compound Lucidin in mice.